Stem Cell Sciences Overview

  • Founded
  • 1994
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 24
Employees
  • Latest Deal Type
  • M&A

Stem Cell Sciences General Information

Description

Provider of drug discovery and cell therapy services. The company specializes in offering cell-based therapies for incurable diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Stem Cells
Primary Office
  • Melbourne, Victoria
  • Australia
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Stem Cell Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Jun-2009 00.00 Completed Generating Revenue
2. IPO 03-Apr-2007 00.00 00.00 00.00 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Stem Cell Sciences’s complete valuation and funding history, request access »

Stem Cell Sciences Executive Team (1)

Name Title Board Seat Contact Info
Hugh Ilyine Vice President & Chief Operating Officer
To view Stem Cell Sciences’s complete executive team members history, request access »

Stem Cell Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Stem Cell Sciences Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Archangel Investors Angel Group Minority 000 0000 000000 0
Biotech Capital Venture Capital Minority 000 0000 000000 0
To view Stem Cell Sciences’s complete investors history, request access »